Biocon Biologics' new mAbs facility receives EU GMP Certification for bBevacizumab

This approval reflects Biocon Biologics' compliance with the highest international regulatory standards

RPG Life Sciences posts Q4 revenue at Rs 118.49 Cr

Revenue from operations at Rs 512.81 crores registered a growth of 17% Y-o-Y for full year FY23

Atul appoints Rangaswamy Iyer as Independent Director

The appointment is effective from May 01, 2023 for five years

Evonik starts construction of new U.S. facility for pharmaceutical lipids

Cooperative agreement with U.S. Government to advance U.S. biopharma industry and ensure pandemic preparedness

TPAG organizes Thalassemia & SCD prevention discussion

The policymakers, doctors and, patient bodies discuss ways to implement thalassemia control programme nationally

PI Industries announces twin acquisitions into Pharma API & CDMO space

Laurus Labs Q4 FY23 consolidated PAT drops to to Rs. 102.98 Cr

Q4 results was challenging driven by steep fall in CDMO revenues and higher upfront cost of Capex projects and R&D projects

Yuyu Pharma unveils the results of its studies for its dry eye treatment peptide

The YP-P10 pre-clinical head-to-head study, jointly conducted by five people including Dr. Kyungho Park of Naason Science

Yasmin and Mirena to take back seat from Bayer’s future drug strategy, says GlobalData

The news on a shift in its focus comes after the refinement of Bayer’s early innovation framework

Cipla partners with MNCs to strengthen anti-diabetes innovative portfolio: GlobalData

Cipla has recently signed an agreement to make and market the diabetes therapy Galvus and its combination brands in India from 01 January 2026.